



AIM: POLB

OTCQB: POLBF

Specialising in the development of innovative medicines to address the unmet need in prevalent and emerging infectious diseases. Poolbeg has a disciplined portfolio approach to mitigate risk, accelerate drug development and enhance investor returns.

Poolbeg has a small molecule immunomodulator (POB 001) which offers significant opportunity across multiple disease areas. The initial data analysis from its LPS human challenge trial indicates a marked reduction in both systemic and localised inflammatory response (full data read-out expected Q2 2023). Other candidates include POLB 002 (respiratory virus infections) and POLB 003 (melioidosis). The Company is also progressing two Oral Delivery Programmes and two Artificial Intelligence Programmes to add promising new assets to its pipeline.

Investment Profile

Near Term Value Inflection Points

- POLB 001 – full data read-out expected Q2 23
- RSV AI programme – lab-based validation stage
- Influenza AI programme – outputs expected in Q2 2023
- DTIF funded Oral Vaccine Platform – Consortium workplan commencement 2023
- Commencement of GLP-1 feasibility Clinical Trial – H1 2023
- POLB 001 expansion to oncology – trial enabling activities in 2023

1

Experienced Team

- Exceptional track record having previously created c. \$2 billion in shareholder value
 - Evident in recent \$1.48bn Amryt deal
- Strong focus on Business Development as partnering discussions continue
- Addition of experienced SAB member

2

Smart, Capital Effective Model

- Disciplined capital allocation – cost effective R&D approach
- Well capitalised with cash balance of £18.9m (30 June 2022)
- Accessing non-dilutive funding opportunities
 - First award: €2.3m for Oral Vaccine Platform

3


Targeting Large Addressable Markets

- Core focus on the booming infectious disease market with expected value >\$250bn by 2025
- Companion therapy in the CAR T cell market which is expected to grow to \$6bn by 2031
- Global obesity sales expected to hit \$30bn by 2030. Global type 2 diabetes market to reach \$58.7bn by 2025

4

Unique Model

Four Steps To Generate Sustainable Shareholder Value
Developing multiple assets at once – reducing risk



Recent infectious disease deals

Increased in-licencing deals by Big Pharma & biotech

GSK acquires Affinivax
\$2.1b upfront + \$1.2b follow-on, May 2022
Pneumococcal vaccine & vaccine platform (Phase II)

Pfizer acquired ReViral
up to \$525m, April 2022
Respiratory Syncytial Virus (RSV) (Preclinical – Phase II assets)

MERCK acquired Oncolmmune
\$425m upfront, Nov 2020
COVID-19 (Phase III)

Bav Nordic licence Chinese rights to Nuance Pharma
\$12.5m upfront + \$200m follow-on, Mar 2022
Respiratory Syncytial Virus (RSV) (Phase III ready)

Pfizer licence rights from LianBio
\$20m upfront + \$135m follow-on, Dec 2022
RSV

Share Price Information

Ticker	AIM: POLB OTCQB: POLBF
Shares in Issue	500m
Market Cap (13/01/23)	c. £47m

Significant Shareholders





Schroder Investment Management	5.13%
Cathal Friel, Co-founder & Chairman	7.28%

Rapidly expanding pipeline of assets developed in-line with capital light model




Addressing global unmet medical need

Pipeline – Clinical Development

Product Candidate	Pre Clinical	Phase I	Phase II	Phase III	Upcoming Catalysts
POLB 001 Severe Influenza treatment					<ul style="list-style-type: none"> LPS challenge trial: full data read-out expected Q2 23 Out-licensing discussions initiated
POLB 001 CAR T cell treatment					<ul style="list-style-type: none"> Clinical trial enabling activities 2023
POLB 002 Respiratory virus infections treatment & prophylactic					<ul style="list-style-type: none"> Development plan completion
POLB 003 Melioidosis vaccine candidate					<ul style="list-style-type: none"> Development plan completion

<p>Global threat of Influenza Pandemic potential</p>  <p>1 in 8 infected annually 5-10 million hospitalisations 500,000 deaths</p>	<p>CAR T Cell Therapy Fast growing market</p>  <p>18-19M cancer cases annually 9.5M+ annual cancer deaths</p>	<p>Respiratory Virus Infections Pandemic potential</p>  <p>5-20% population infected 3M+ annual deaths Top 5 global cause of death</p>	<p>Growing threat of Melioidosis Climate change & antibiotic resistance</p>  <p>c. 165,000 infected annually c. 54% of cases are fatal 0 vaccines available</p>
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Product Platforms

Partner	Target Discovery	Product Validation	Animal Efficacy	IND Enabling	Upcoming Catalysts	
AI Programme 1 RSV therapeutics 					<ul style="list-style-type: none"> Lab-based validation 	
AI Programme 2 Influenza drug targets 					<ul style="list-style-type: none"> Outputs expected Q2 '23 	
Oral Delivery Platform Licenced targeted delivery system 	<i>Validated Technology & grant funded</i>		V a c c i n e s			<ul style="list-style-type: none"> Consortium workplan commencement Clinical trial commencement - H1 2023
	<i>Validated Technologies</i>		M e t a b o l i c D i s e a s e s			

<p>Respiratory Syncytial Virus (RSV) </p> <p>50m infected annually 4m hospitalisations 74,500 deaths in children <5</p>	<p>Artificial Intelligence </p> <p>The first time human challenge trial data is analysed using AI to identify new drug targets & treatments</p>	<p>Oral Delivery Platform </p> <p>A delivery system solution for the oral delivery of oral vaccines and also GLP-1 / metabolic peptide cargo to specific areas of the gut</p>
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

<p>POLB 001</p>	<p>Potent anti-inflammatory immunomodulator May have utility across several diseases</p>	<p>Hyper-inflammation: a source of toxicity in many patient groups This includes <i>severe influenza</i> and <i>CAR T cell patients</i></p>	<p>LPS trial results Potentially indicative of usefulness in other forms of cytokine release syndrome</p>
------------------------	-----------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------

Stay in touch



IR@PoolbegPharma.com



@PoolbegPharma



www.PoolbegPharma.com



@PoolbegPharma



Sign up for RNS alerts